Domů › Kolorektální karcinom › Colorado › Denver
Klinické studie Kolorektální karcinom v Denver, CO
23 studií pro Kolorektální karcinom hledá účastníky v lokalitách v Denver a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
The Vanguard Study: Testing a New Way to Screen for Cancer
Probíhá náborVítáni zdraví dobrovolníci
- Kaiser Permanente-Franklin, Denver
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Probíhá náborFáze 1/2
- Rocky Mountain Cancer Center, Denver
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Probíhá náborObservační studieVítáni zdraví dobrovolníci
- AdventHealth Porter, Denver
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Probíhá náborFáze 3
- Intermountain Health Cancer Center Saint Joseph, Denver
- Intermountain Health Saint Joseph Hospital - Research Office, Denver
- Intermountain Health Saint Joseph Hospital, Denver
- a dalších 3
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Probíhá náborFáze 1/2
- Sarah Cannon Research Institute (SCRI), Denver
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Probíhá náborFáze 3
- Rocky Mountain Cancer Centers, Denver
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Probíhá náborFáze 3
- Rocky Mountain Cancer Centers, Denver
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Probíhá náborFáze 1/2
- SCRI at HCA Health One, Denver
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Probíhá náborFáze 1
- SCRI Denver, Denver
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Probíhá náborFáze 1
- Sarah Cannon Research Institute at HealthOne, Denver
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Probíhá náborFáze 1
- Sarah Cannon Research Institute, Denver
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Probíhá náborFáze 1/2
- Rocky Mountain Cancer Center, Denver
- Sarah Cannon Research Institute at HealthONE, Denver
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Probíhá náborFáze 1
- Sarah Cannon Research Institue At Healthone, Denver
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Probíhá náborFáze 3
- Rocky Mountain Cancer Centers, LLP, Denver
- Rocky Mountain Cancer Centers, LLP, Denver
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Probíhá náborFáze 1
- Sarah Cannon Research Institute at HealthONE, Denver
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Probíhá náborFáze 1
- Context Investigational Site, Denver
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
Probíhá náborFáze 2
- Rocky Mountain Cancer Center - Primary, Denver
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Probíhá náborFáze 1
- Sarah Cannon Research Institute at HealthONE, Denver
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Probíhá náborFáze 1/2
- SCRI - Denver, Denver
Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer
Probíhá náborObservační studieVítáni zdraví dobrovolníci
- Department of Medicine-Gastroenterology, Denver Veterans Affairs Medical Center, University of Colorado Hospital, Denver
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Probíhá náborFáze 1
- Sarah Cannon Cancer Institute at HealthONE, Denver
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Probíhá náborObservační studie
- Kaiser Permanente-Franklin, Denver
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Centers-Midtown, Denver
- a dalších 1
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Probíhá náborFáze 1/2
- Sarah Cannon Research Institute at HealthONE, Denver
Studie Kolorektální karcinom v jiných městech
- Houston, TX102 studií
- New York City, NY78 studií
- Nashville, TN69 studií
- Boston, MA63 studií
- Los Angeles, CA59 studií
- Arlington, VA52 studií
- St. Louis, MO50 studií
- San Antonio, TX46 studií
- Philadelphia, PA44 studií
- Grand Rapids, MI40 studií
- Baldwin Park, CA37 studií
- Chicago, IL34 studií
Další studie v Denver
- Metastatický karcinom29 studií
- Rakovina prsu29 studií
- Nemalobuněčný plicní karcinom27 studií
- Mnohočetný myelom27 studií
- Melanom19 studií
- Rakovina prostaty19 studií
- Rakovina (všechny typy)18 studií
- Rakovina vaječníků16 studií
- Rakovina plic16 studií
- Rakovina endometria15 studií
- Non-Hodgkinův lymfom14 studií
- Rakovina slinivky břišní13 studií
Zdroj: ClinicalTrials.gov, data načtena 6. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.